TransMedics Group (TMDX) Tops Q4 EPS by 19c, provides guidance

TransMedics Group (NASDAQ: TMDX) reported Q4 EPS of $0.12, $0.19 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $81.2 million versus the consensus estimate of $68.49 million.

GUIDANCE:

TransMedics Group sees FY2024 revenue of $360-370 million, versus the consensus of $330.2 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• McGraw Hill (MH) Tops Q1 EPS by 15c, Beats on Revenue; Offers FY26 Revenue Guidance
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00